Jane Jesse
Psychiatry · Kingston, PANPI 1508060112
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $509,096 of the $616,754 with a category attached, or 82.5%. Teva Pharmaceuticals USA, Inc. accounts for 93.0% of it on its own, with 20 other manufacturers making up the rest. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,061 payments — averaging $581.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$574K
- AbbVie$40K
- Otsuka America Pharmaceutical, Inc.$558
- Vanda Pharmaceuticals Inc.$440
- Johnson & Johnson$436
- Takeda Pharmaceuticals U.S.A., Inc.$393
- plus $2K from 15 others
What the payments were for
- Consulting fees$35,0156%
- Speaking & faculty fees$509,09683%
- Travel & lodging$54,4219%
- Food & beverage$17,6703%
- Education$5520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 728 | $573,850 |
| AbbVie(2 entities) | 127 | $39,513 |
| Otsuka America Pharmaceutical, Inc. | 29 | $558 |
| Vanda Pharmaceuticals Inc. | 25 | $440 |
| Johnson & Johnson | 28 | $436 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $393 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $338 |
| Alkermes, Inc. | 17 | $265 |
| Sunovion Pharmaceuticals Inc. | 18 | $193 |
| Lundbeck LLC | 10 | $173 |
| Indivior Inc. | 8 | $138 |
| Axsome Therapeutics, Inc. | 6 | $116 |
| Shire North American Group Inc | 7 | $112 |
| Neurocrine Biosciences, Inc. | 3 | $67 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Neuronetics, Inc. | 1 | $32 |
| Ironshore Pharmaceuticals Inc. | 2 | $26 |
| Neos Therapeutics, LP | 2 | $26 |
| Bausch Health US, LLC | 1 | $17 |
| Braeburn Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$284,818
- Austedo XR$141,038
- UZEDY$136,963
- VRAYLAR$37,790
How this compares
$616,754 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $218,374 |
| AristadaAripiprazole Lauroxil | 11 | $33,001 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,040 |
| Duloxetine Hcl | 52 | $1,276 |
| Fluoxetine Hcl | 38 | $913 |
| Lamotrigine | 27 | $553 |
| Bupropion XlBupropion Hcl | 15 | $417 |
| Aripiprazole | 15 | $402 |
| Clonazepam | 54 | $394 |
| Olanzapine | 14 | $313 |
| Citalopram HbrCitalopram Hydrobromide | 16 | $246 |
| Quetiapine Fumarate | 19 | $242 |
| Lorazepam | 23 | $235 |
| Alprazolam | 31 | $228 |
| Escitalopram Oxalate | 16 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $573,850 | $218,37428 claims |
| Alkermes, Inc.Aristada | $265 | $33,00111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $393 | $5,04011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Kingston
- Mark SaxonKingston$21K
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.